141 completed, 27 terminated, 24 recruiting, 17 active not recruiting. 124 Phase 1, 53 Phase 2, 33 Phase 3, 9 Phase 4, 4 Not applicable.
Follow Astellas Pharma Global Development, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-10-22 |
| Fezolinetant and Vascular Health and Brain Health Placebo, Fezolinetant - Menopause Hot Flashes | Phase 3 | Not yet recruiting | Rebecca Thurston | 220 | 2026-09-25 | 2026-08-19 |
| A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer fezolinetant, enzalutamide, apalutamide - Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 56 | 2026-09-25 | 2026-10-16 |
| A Natural History Study of Angelman Syndrome Angelman Syndrome, Neurodevelopmental Conditions | Recruiting | Massachusetts General Hospital | 40 | 2026-09-09 | 2026-10-13 | |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-09-18 |
| A Study to Learn How ASP3082 is Processed in Healthy Men 14C-labeled ASP3082 - Healthy Volunteer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 8 | 2026-08-28 | 2026-10-07 |
| A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer ASP2138, Pembrolizumab, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 570 | 2026-07-28 | 2026-10-22 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-19 |
| A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors ASP546C - Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 150 | 2026-05-04 | 2026-09-22 |
| A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation Setidegrasib, Docetaxel - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 356 | 2026-04-28 | 2026-10-20 |
| A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder Enfortumab Vedotin, Pembrolizumab - Muscle-invasive Bladder Cancer | Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 240 | 2026-03-12 | 2026-10-22 |
| A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults No Intervention - Stargardt Disease, Stargardt Macular Dystrophy | Recruiting | Astellas Pharma Global Development, Inc. | 90 | 2026-02-20 | 2026-10-20 | |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Setidegrasib, Oxaliplatin, Leucovorin - Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 614 | 2026-02-17 | 2026-09-22 |
| A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors ASP2998, Pembrolizumab, Enfortumab Vedotin - Locally Advanced or Metastatic Malignant Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 428 | 2026-02-05 | 2026-10-22 |
| A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults Setidegrasib, Fluconazole, Carbamazepine - Healthy Volunteer | Phase 1 | Active not recruiting | Astellas Pharma Global Development, Inc. | 54 | 2026-02-03 | 2026-08-27 |
| A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer ASP5541, Prednisone - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 12 | 2026-01-20 | 2026-02-18 |
| A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer ASP2138, Oxaliplatin, Leucovorin - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 25 | 2025-10-16 | 2026-09-02 |
| A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer zolbetuximab, mFOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | Astellas Pharma Global Development, Inc. | 12 | 2025-09-24 | 2026-10-16 |
| A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) gilteritinib - Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 40 | 2025-09-22 | 2026-10-23 |
Showing 20 of 225. Sign in to see all of them.
Neoplasms (20) · Leukemia, Myeloid, Acute (17) · Carcinoma, Non-Small-Cell Lung (14) · Prostatic Neoplasms (13) · Adenocarcinoma (8) · Hot Flashes (8) · Arthritis, Rheumatoid (7) · Carcinoma, Transitional Cell (6) · Neoplasm Metastasis (6) · Stomach Neoplasms (5) · Urinary Bladder Neoplasms (5) · Breast Neoplasms (4) · Ovarian Neoplasms (4) · Urinary Bladder, Overactive (4) · Coronary Artery Disease (3)
isavuconazole (25) · gilteritinib (20) · pembrolizumab (20) · fezolinetant (14) · Oxaliplatin (13) · enzalutamide (13) · Fluorouracil (12) · enfortumab vedotin (12) · Leucovorin (10) · zolbetuximab (10) · Prednisone (8) · Capecitabine (7) · Docetaxel (7) · Carboplatin (6) · mirabegron (6)
United States (192) · Canada (47) · Spain (42) · Germany (36) · Japan (35) · United Kingdom (35) · Italy (34) · France (33) · South Korea (30) · Taiwan (25) · Poland (24) · Australia (22) · Belgium (21) · China (16) · Czechia (16)
PMID 32304015, PMID 39739195, PMID 36041086, PMID 37990323, PMID 38010254, PMID 38396203, PMID 38775925, PMID 38861294, PMID 40044127, PMID 40680855, PMID 41259888, PMID 42095986, PMID 16353442, PMID 17194875, PMID 23377438, PMID 25683285, PMID 26343110, PMID 26607361, PMID 26904404, PMID 27310327, PMID 27878567, PMID 28118538, PMID 28224449, PMID 28645776, PMID 29596222, PMID 29745007, PMID 30962330, PMID 31070709, PMID 31329516, PMID 31410787, PMID 31509331, PMID 31665578, PMID 32102086, PMID 32183741, PMID 32336645, PMID 32414772, PMID 32533536, PMID 32725584, PMID 32734597, PMID 33068028, PMID 33170593, PMID 33203954, PMID 33328761, PMID 33358484, PMID 33558294, PMID 33577729, PMID 33591468, PMID 33830407, PMID 33842870, PMID 34008425
2018 (13), 2023 (7), 2015 (6), 2016 (6), 2017 (4), 2019 (3), 2025 (3), 2014 (2), UG3DA051392 (2), 1RC2HL101367-01 (1), K23HL119620 (1)